Your browser is no longer supported. Please, upgrade your browser.
Acasti Pharma Inc.
Index- P/E- EPS (ttm)-1.39 Insider Own12.09% Shs Outstand26.05M Perf Week0.87%
Market Cap101.88M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float20.63M Perf Month-20.05%
Income-22.70M PEG- EPS next Q- Inst Own0.95% Short Float3.23% Perf Quarter-54.34%
Sales0.20M P/S509.40 EPS this Y45.00% Inst Trans- Short Ratio0.76 Perf Half Y-50.70%
Book/sh2.57 P/B0.68 EPS next Y- ROA-43.40% Target Price2.00 Perf Year5.13%
Cash/sh1.23 P/C1.41 EPS next 5Y- ROE-50.50% 52W Range1.37 - 9.76 Perf YTD-33.27%
Dividend- P/FCF- EPS past 5Y22.50% ROI- 52W High-82.22% Beta1.50
Dividend %- Quick Ratio- Sales past 5Y39.10% Gross Margin61.20% 52W Low26.83% ATR0.12
Employees32 Current Ratio25.80 Sales Q/Q- Oper. Margin- RSI (14)32.26 Volatility4.80% 6.05%
OptionableNo Debt/Eq0.00 EPS Q/Q70.90% Profit Margin- Rel Volume0.28 Prev Close1.74
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume872.32K Price1.74
Recom- SMA20-11.32% SMA50-33.60% SMA200-58.78% Volume243,234 Change-0.29%
Sep-01-20Downgrade Oppenheimer Outperform → Perform
Jul-06-20Upgrade B. Riley FBR Neutral → Buy $2
Jan-13-20Downgrade B. Riley FBR Buy → Neutral
Aug-29-19Initiated B. Riley FBR Buy $7.75
Jul-18-19Initiated Oppenheimer Outperform $7
Jun-26-19Initiated H.C. Wainwright Buy $6
Oct-07-21 10:15AM  
Oct-06-21 08:30AM  
Sep-27-21 08:30AM  
Sep-22-21 08:30AM  
Sep-14-21 08:30AM  
Sep-08-21 08:30AM  
Aug-31-21 02:27PM  
Aug-27-21 08:40AM  
Aug-25-21 07:02AM  
Aug-12-21 07:00AM  
Jul-29-21 08:30AM  
Jul-23-21 08:30AM  
Jul-07-21 09:00AM  
Jul-06-21 11:02AM  
Jul-03-21 06:52PM  
Jun-24-21 03:22AM  
Jun-23-21 08:27AM  
Jun-22-21 07:00AM  
Jun-14-21 04:20PM  
May-17-21 07:00AM  
May-13-21 06:05PM  
May-12-21 05:31PM  
May-07-21 11:53AM  
Mar-08-21 05:30PM  
Feb-09-21 06:55AM  
Jan-27-21 06:55AM  
Dec-25-20 12:00PM  
Dec-23-20 03:24PM  
Nov-16-20 06:55AM  
Nov-12-20 05:43AM  
Oct-01-20 04:30PM  
Sep-29-20 06:55AM  
Sep-16-20 06:55AM  
Sep-11-20 07:00AM  
Sep-01-20 02:10PM  
Aug-31-20 07:00AM  
Aug-14-20 12:00PM  
Aug-13-20 08:30AM  
Jul-31-20 07:55AM  
Jul-06-20 02:37PM  
Jun-29-20 09:45AM  
Jun-19-20 08:00AM  
Jun-04-20 09:49PM  
May-06-20 06:25AM  
Apr-30-20 08:30AM  
Apr-20-20 08:30AM  
Apr-01-20 08:30AM  
Mar-11-20 08:00AM  
Mar-06-20 06:50AM  
Feb-28-20 05:00PM  
Feb-14-20 11:41AM  
Feb-13-20 09:00AM  
Feb-11-20 11:27AM  
Feb-10-20 07:00AM  
Jan-17-20 11:07AM  
Jan-14-20 09:46AM  
Jan-13-20 04:22PM  
Jan-10-20 10:59AM  
Jan-09-20 08:56AM  
Dec-24-19 09:51AM  
Dec-23-19 08:31PM  
Dec-22-19 04:43PM  
Dec-20-19 04:41AM  
Nov-26-19 07:55AM  
Nov-25-19 08:30AM  
Nov-21-19 08:23AM  
Nov-18-19 08:38AM  
Nov-13-19 07:55AM  
Nov-07-19 08:30AM  
Nov-06-19 09:00AM  
Nov-04-19 09:04AM  
Oct-01-19 09:00AM  
Sep-30-19 08:35AM  
Sep-27-19 06:05AM  
Sep-09-19 08:30AM  
Sep-04-19 09:00AM  
Aug-28-19 04:05PM  
Aug-14-19 08:00AM  
Aug-09-19 08:00AM  
Aug-07-19 08:00AM  
Jul-25-19 03:42PM  
Jul-05-19 08:35AM  
Jun-26-19 11:08AM  
Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre, an omega-3 phospholipid therapeutic to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.